Loss of Spry1 reduces growth of BRAFV600-mutant cutaneous melanoma and improves response to targeted therapy

ROS signalling in the biology of cancer

(2018) Jennifer N. Moloney et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

Hyperactivation of MAPK Signaling is Deleterious to RAS/RAF Mutant Melanoma

(2018) Grace P Leung et al.   MOLECULAR CANCER RESEARCH

The mitogen-activated protein kinase pathway in melanoma part I – Activation and primary resistance mechanisms to BRAF inhibition

(2017) Teresa Amaral et al.   EUROPEAN JOURNAL OF CANCER

HCMDB: the human cancer metastasis database

(2017) Guantao Zheng et al.   NUCLEIC ACIDS RESEARCH

Exon 3 mutations of CTNNB1 drive tumorigenesis: a review

(2017) Chao Gao et al.   Oncotarget

LKB1 loss cooperating with BRAF V600E promotes melanoma cell invasion and migration by up-regulation MMP-2 via PI3K/Akt/mTOR pathway

(2017) Weiming Zhang et al.   Oncotarget

BTG2 is a tumor suppressor gene upregulated by p53 and PTEN in human bladder carcinoma cells

(2017) Ke-Hung Tsui et al.   Cancer Medicine

Identification of Biomarkers Correlated with the TNM Staging and Overall Survival of Patients with Bladder Cancer

(2017) Sheng Li et al.   Frontiers in Physiology

UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses

(2017) Darshan S. Chandrashekar et al.   NEOPLASIA

Negative feedback regulation of the ERK1/2 MAPK pathway

(2016) David Lake et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Targeting the hedgehog transcription factors GLI1 and GLI2 restores sensitivity to vemurafenib-resistant human melanoma cells

(2016) F Faião-Flores et al.   ONCOGENE

EWS-FLI1-mediated suppression of the RAS-antagonist Sprouty 1 (SPRY1) confers aggressiveness to Ewing sarcoma

(2016) F Cidre-Aranaz et al.   ONCOGENE

Oncogenic BRAF-Mediated Melanoma Cell Invasion

(2016) Hezhe Lu et al.   Cell Reports

Toll-Like Receptor 1/2 and 5 Ligands Enhance the Expression of Cyclin D1 and D3 and Induce Proliferation in Mantle Cell Lymphoma

(2016) Katy Mastorci et al.   PLoS One

Vemurafenib Resistance Signature by Proteome Analysis Offers New Strategies and Rational Therapeutic Concepts

(2015) V. Paulitschke et al.   MOLECULAR CANCER THERAPEUTICS

Atypical role of sprouty in colorectal cancer: sprouty repression inhibits epithelial–mesenchymal transition

(2015) Q Zhang et al.   ONCOGENE

Inhibition of vemurafenib-resistant melanoma by interference with pre-mRNA splicing

(2015) Maayan Salton et al.   Nature Communications

MT1-MMP dependent repression of the tumor suppressor SPRY4 contributes to MT1-MMP driven melanoma cell motility

(2015) Khvaramze Shaverdashvili et al.   Oncotarget

HTSeq--a Python framework to work with high-throughput sequencing data

(2014) S. Anders et al.   BIOINFORMATICS

Trimmomatic: a flexible trimmer for Illumina sequence data

(2014) Anthony M. Bolger et al.   BIOINFORMATICS

The developing story of Sprouty and cancer

(2014) Samar Masoumi-Moghaddam et al.   CANCER AND METASTASIS REVIEWS

Immunohistochemistry with the anti-BRAF V600E (VE1) antibody: impact of pre-analytical conditions and concordance with DNA sequencing in colorectal and papillary thyroid carcinoma

(2014) Katerina Dvorak et al.   PATHOLOGY

A Collagen-Remodeling Gene Signature Regulated by TGF-β Signaling Is Associated with Metastasis and Poor Survival in Serous Ovarian Cancer

(2013) Dong-Joo Cheon et al.   CLINICAL CANCER RESEARCH

microRNA 21-mediated suppression of sprouty1 by Pokemon affects liver cancer cell growth and proliferation

(2013) Xiu-Li Jin et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Sprouty2, PTEN, and PP2A interact to regulate prostate cancer progression

(2013) Rachana Patel et al.   JOURNAL OF CLINICAL INVESTIGATION

MCJ/DnaJC15, an Endogenous Mitochondrial Repressor of the Respiratory Chain That Controls Metabolic Alterations

(2013) K. M. Hatle et al.   MOLECULAR AND CELLULAR BIOLOGY

Genome engineering using the CRISPR-Cas9 system

(2013) F Ann Ran et al.   Nature Protocols

SPROUTY2 is a β-catenin and FOXO3a target gene indicative of poor prognosis in colon cancer

(2013) P Ordóñez-Morán et al.   ONCOGENE

AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma

(2013) W Hu et al.   Cell Death & Disease

STAR: ultrafast universal RNA-seq aligner

(2012) Alexander Dobin et al.   BIOINFORMATICS

Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas

(2012) Piro Lito et al.   CANCER CELL

Melanoma: from mutations to medicine

(2012) H. Tsao et al.   GENES & DEVELOPMENT

Identification of Genomic Targets of Transcription Factor Aebp1 and its role in Survival of Glioma Cells

(2012) J. Ladha et al.   MOLECULAR CANCER RESEARCH

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.

(2012) Ethan Cerami et al.   Cancer Discovery

Silencing of SPRY1 Triggers Complete Regression of Rhabdomyosarcoma Tumors Carrying a Mutated RAS Gene

(2010) G. Schaaf et al.   CANCER RESEARCH

Fgf9 signalling stimulates Spred and Sprouty expression in embryonic mouse pancreas mesenchyme

(2010) Kathrine B. Sylvestersen et al.   GENE EXPRESSION PATTERNS

Fibroblast growth factor-2 regulation of sprouty and NR4A genes in bovine ovarian granulosa cells

(2010) Z.L. Jiang et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Sprouty-2 controls c-Met expression and metastatic potential of colon cancer cells: sprouty/c-Met upregulation in human colonic adenocarcinomas

(2010) C Holgren et al.   ONCOGENE

Sprouty proteins: modified modulators, matchmakers or missing links?

(2009) G R Guy et al.   JOURNAL OF ENDOCRINOLOGY

Intermolecular Interactions of Sprouty Proteins and Their Implications in Development and Disease

(2009) F. Edwin et al.   MOLECULAR PHARMACOLOGY

V600EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway

(2009) C. A. Pratilas et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA